Court Dismisses Most of Class-Action Lawsuit From 2011 TRICARE Data Breach

A federal judge has dismissed most of the TRICARE recipients from the class-action lawsuit filed against TRICARE and Science Applications International Corporation, a scientific, engineering and technology applications company, which was filed as a result of a 2011 data breach.

Advertisement

The 2011 breach occurred when backup tapes from an electronic health record used by TRICARE were stolen from an SAIC employee’s vehicle.

As a result of the breach, multiple class-action lawsuits were filed against TRICARE and SAIC by the affected recipients alleging they faced an increased risk of identity theft as a result of their medical records being stolen. All of the lawsuits were consolidated in Washington, D.C.

The D.C. federal judge dismissed 31 of the 33 TRICARE recipients named in the consolidated lawsuit. In support of the dismissal the court stated the degree to which the recipients’ risk of identity theft is increased due to the data breach is irrelevant because it is not an “actual injury.” The plaintiffs must show “harm is certainly impending,” which many of them failed to do.

Plaintiffs who suffered identity theft as a result of the data breach remain as named plaintiffs in the consolidated case.

More Articles on Data Breaches:

FTC Responds to LabMD’s Motion For Summary Determination 
1,981 Baylor Regional Medical Center Patients’ Information Compromised By Phishing Scheme 
Insider Breach at BCBS of Kansas City Affects 2,546 Members

 

Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit

Advertisement

Next Up in Legal & Regulatory Issues

Advertisement

Comments are closed.